Barclays
COLL icon

Barclays’s Collegium Pharmaceutical COLL Stock Holding History

Barclays’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,000
Closed -$701K – 6777
2016
Q4 		$701K Hold
45,000
– – ﹤0.01% 3083
2016
Q3 		$867K Buy
+45,000
New +$534K ﹤0.01% 2756

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Barclays's COLL Position: Q1 2026 in Review

Barclays reduced its Collegium Pharmaceutical (COLL) stake by 31% in Q1 2026, selling an estimated $1.34M and leaving 71,949 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Barclays first reported a position in COLL in Q2 2015 and has held it in 44 quarters since. The position peaked at $4.8M in Q4 2025. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Barclays held 71,949 shares of Collegium Pharmaceutical worth $2.38M as of Q1 2026.
  • Barclays sold 31,660 Collegium Pharmaceutical shares in Q1 2026, an estimated $1.34M.
  • Collegium Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2236 holding.
  • Barclays first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 44 quarters since.
  • Barclays's Collegium Pharmaceutical position peaked at $4.8M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.